In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages 4324-4332

  Brody, Joshua D ^a   Ai, Weiyun Z ^a   Czerwinski, Debra K ^a   Torchia, James A ^a   Levy, Mia ^a   Advani, Ranjana H ^a   Kim, Youn H ^a   Hoppe, Richard T ^a   Knox, Susan J ^a   Shin, Lewis K ^a   Wapnir, Irene ^a   Tibshirani, Robert J ^a   Levy, Ronald ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; CANCER VACCINE; OLIGODEOXYRIBONUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEVER; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MYALGIA; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; IMMUNOLOGY; INNATE IMMUNITY; INTRALESIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; CANCER VACCINES; FEMALE; HUMANS; IMMUNITY, INNATE; INJECTIONS, INTRALESIONAL; LOGISTIC MODELS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 78049420571     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.9793     Document Type: Article

References (41)

1. Rohatiner AZ, Lister TA: The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 18:1-10, 2005 (Pubitemid 40197862)
2. Higano CS, Schellhammer PF, Small EJ, et al: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679, 2009
3. Di Nicola M, Zappasodi R, Carlo-Stella C, et al: Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: A pilot study. Blood 113:18-27, 2009
4. Kwak LW, Campbell MJ, Czerwinski DK, et al: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209-1215, 1992
5. Freedman A, Neelapu SS, Nichols C, et al: Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocytemacrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27:3036-3043, 2009
6. Levy R, Robertson M, Ganjoo K, et al: Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). AACR Meeting Abstracts 2008 (abstr LB-204)
7. Schuster SN, Gause SS, Muggia BL, et al: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 27:5s, 2009 (suppl; abstr 2)
8. Li J, Song W, Czerwinski DK, et al: Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 179:2493-2500, 2007
9. Varghese B, Widman A, Do J, et al: Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood 114:4477-4485, 2009
10. Bourke E, Bosisio D, Golay J, et al: The toll-like receptor repertoire of human B lymphocytes: Inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102:956-963, 2003 (Pubitemid 36917790)
11. Haas RL, Poortmans P, de Jong D, et al: High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21:2474-2480, 2003 (Pubitemid 46606327)
12. Leonard JP, Link BK, Emmanouilides C, et al: Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 13:6168-6174, 2007 (Pubitemid 350075077)
13. Link BK, Ballas ZK, Weisdorf D, et al: Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29:558-568, 2006 (Pubitemid 44395280)
14. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
15. Levy MA, Garg A, Tam A, et al: LesionViewer: A tool for tracking cancer lesions over time. AMIA Annu Symp Proc 2007:443-447, 2007
16. Ribas A, Camacho LH, Lopez-Berestein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968-8977, 2005 (Pubitemid 46217464)
17. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, et al: B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 11:1490-1499, 2005 (Pubitemid 40315231)
18. Decker T, Schneller F, Sparwasser T, et al: Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95:999-1006, 2000 (Pubitemid 30062724)
19. Brody JD, Goldstein MJ, Czerwinski DK, et al: Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 113:85-94, 2009
20. Ai WZ, Hou JZ, Zeiser R, et al: Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 124:239-244, 2009
21. Yang ZZ, Novak AJ, Stenson MJ, et al: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646, 2006
22. Inoges S, Rodrìguez-Calvillo M, Zabalegui N, et al: Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292-1301, 2006 (Pubitemid 44530725)
23. Redfern CH, Guthrie TH, Bessudo A, et al: Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 24:3107-3112, 2006 (Pubitemid 46638948)
24. Timmerman JM, Czerwinski DK, Davis TA, et al: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99:1517-1526, 2002 (Pubitemid 34533020)
25. Fournier P, Schirrmacher V: Randomized clinical studies of anti-tumor vaccination: State of the art in 2008. Expert Rev Vaccines 8:51-66, 2009
26. Sosman JA, Carrillo C, Urba WJ, et al: Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 26:2292-2298, 2008
27. Hofmann MA, Kors C, Audring H, et al: Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31:520-527, 2008
28. Molenkamp BG, Sluijter BJ, van Leeuwen PA, et al: Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532-4542, 2008
29. Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61, 2007 (Pubitemid 46067386)
30. Neelapu SS, Kwak LW, Kobrin CB, et al: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11:986-991, 2005 (Pubitemid 41294445)
31. Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-6276, 2009
32. Deng Y, Jing Y, Campbell AE, et al: Age-related impaired type 1 T cell responses to influenza: Reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172:3437-3446, 2004 (Pubitemid 38337923)
33. Kim SH, Choi SJ, Park WB, et al: Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 25:6287-6291, 2007 (Pubitemid 47088029)
34. Treanor J, Wu H, Liang H, et al: Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary small-pox vaccination of adults. Vaccine 24:6913-6923, 2006 (Pubitemid 46107183)
35. Carreras J, Lopez-Guillermo A, Fox BC, et al: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957-2964, 2006
36. Tzankov A, Meier C, Hirschmann P, et al: Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93:193-200, 2008 (Pubitemid 351397707)
37. Krieg AM, Efler SM, Wittpoth M, et al: Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27:460-471, 2004 (Pubitemid 39447354)
38. Houot R, Levy R: Idiotype vaccination for lymphoma: Moving towards optimisation. Leuk Lymphoma 50:1-2, 2009
39. Najar HM, Dutz JP: Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J Invest Dermatol 128:2204-2210, 2008
40. VanOosten RL, Griffith TS: Activation of tumor-specific CD8+ T cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 67:11980-11990, 2007
41. Meng Y, Carpentier AF, Chen L, et al: Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116:992-997, 2005 (Pubitemid 41209208)